The clinical utility of prostate cancer heterogeneity using texture analysis of multiparametric MRI.

Image enhancement Magnetic resonance imaging Neoplasm grading Prostate-specific antigen Prostatic neoplasms Radical prostatectomy Texture analysis

Journal

International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521

Informations de publication

Date de publication:
May 2019
Historique:
received: 16 02 2019
accepted: 21 03 2019
pubmed: 1 4 2019
medline: 10 1 2020
entrez: 1 4 2019
Statut: ppublish

Résumé

To determine if multiparametric MRI (mpMRI) derived filtration-histogram based texture analysis (TA) can differentiate between different Gleason scores (GS) and the D'Amico risk in prostate cancer. We retrospectively studied patients whose pre-operative 1.5T mpMRI had shown a visible tumour and who subsequently underwent radical prostatectomy (RP). Guided by tumour location from the histopathology report, we drew a region of interest around the dominant visible lesion on a single axial slice on the T2, Apparent Diffusion Coefficient (ADC) map and early arterial phase post-contrast T1 image. We then performed TA with a filtration-histogram software (TexRAD -Feedback Medical Ltd, Cambridge, UK). We correlated GS and D'Amico risk with texture using the Spearman's rank correlation test. We had 26 RP patients with an MR-visible tumour. Mean of positive pixels (MPP) on ADC showed a significant negative correlation with GS at coarse texture scales. MPP showed a significant negative correlation with GS without filtration and with medium filtration. MRI contrast texture without filtration showed a significant, negative correlation with D'Amico score. MR T2 texture showed a significant, negative correlation with the D'Amico risk, particularly at textures without filtration, medium texture scales and coarse texture scales. ADC map mpMRI TA correlated negatively with GS, and T2 and post-contrast images with the D'Amico risk score. These associations may allow for better assessment of disease prognosis and a non-invasive method of follow-up for patients on surveillance. Further, identifying clinically significant prostate cancer is essential to reduce harm from over-diagnosis and over-treatment.

Identifiants

pubmed: 30929224
doi: 10.1007/s11255-019-02134-0
pii: 10.1007/s11255-019-02134-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

817-824

Subventions

Organisme : UK Department of Health National Institute of Health Research
ID : n/a
Organisme : UK Department of Health National Institute of Health Research
ID : n/a
Organisme : London North West Healthcare Charitable Fund
ID : n/a
Organisme : UCL Experimental Cancer Medicine Centre
ID : n/a

Commentaires et corrections

Type : ErratumIn

Références

N Engl J Med. 2001 May 3;344(18):1373-7
pubmed: 11333995
J Urol. 2008 Nov;180(5):1964-7; discussion 1967-8
pubmed: 18801515
Radiology. 2008 Dec;249(3):900-8
pubmed: 19011187
Radiology. 2009 Feb;250(2):444-52
pubmed: 19164695
J Magn Reson Imaging. 2009 Aug;30(2):327-34
pubmed: 19629981
Prostate Cancer Prostatic Dis. 2010 Mar;13(1):71-7
pubmed: 19786982
J Clin Oncol. 2010 Jan 1;28(1):126-31
pubmed: 19917860
World J Urol. 2010 Dec;28(6):667-72
pubmed: 20623288
Radiology. 2010 Dec;257(3):715-23
pubmed: 20843992
BJU Int. 2011 May;107(9):1411-8
pubmed: 21044250
Eur Urol. 2011 Apr;59(4):477-94
pubmed: 21195536
Clin Radiol. 2012 Feb;67(2):157-64
pubmed: 21943720
Eur Radiol. 2012 Apr;22(4):796-802
pubmed: 22086561
Neurol Res Int. 2012;2012:195176
pubmed: 22203901
Eur Radiol. 2012 Apr;22(4):746-57
pubmed: 22322308
Insights Imaging. 2012 Dec;3(6):573-89
pubmed: 23093486
BJU Int. 2013 May;111(5):753-60
pubmed: 23464824
Eur Radiol. 2013 Jul;23(7):2019-29
pubmed: 23494494
Cancer Imaging. 2013 Sep 23;13(3):400-6
pubmed: 24061266
Eur Urol. 2014 Jan;65(1):124-37
pubmed: 24207135
Radiology. 2014 Apr;271(1):143-52
pubmed: 24475824
Radiology. 2014 Jul;272(1):100-12
pubmed: 24654970
Eur Radiol. 2015 Feb;25(2):523-32
pubmed: 25226842
Invest Radiol. 2015 Apr;50(4):239-45
pubmed: 25501017
Eur Radiol. 2015 Oct;25(10):2840-50
pubmed: 25991476
Int Urol Nephrol. 2016 Apr;48(4):529-33
pubmed: 26759330
Eur Radiol. 2017 Jun;27(6):2348-2358
pubmed: 27620864
Int J Mol Sci. 2017 Apr 12;18(4):null
pubmed: 28417929
Eur Radiol. 2017 Dec;27(12):5290-5298
pubmed: 28608163
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Breast J. 2019 May;25(3):373-380
pubmed: 29602210
J Magn Reson Imaging. 2018 Dec;48(6):1637-1647
pubmed: 30102441
JAMA. 1998 Sep 16;280(11):969-74
pubmed: 9749478

Auteurs

Maira Hameed (M)

Department of Radiology, Imperial College Healthcare NHS Trust, South Wharf Road, London, UK.

Balaji Ganeshan (B)

Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, Euston Road, London, UK.

Joshua Shur (J)

Joint Department of Medical Imaging, University Health Network, Toronto, Canada.

Subhabrata Mukherjee (S)

Department of Urology, Dartford and Gravesham NHS Trust, Darenth Wood Road, Dartford, UK.

Asim Afaq (A)

Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, Euston Road, London, UK.

Deepak Batura (D)

Department of Urology, London North West University Healthcare NHS Trust, Watford Road, London, UK. deepakbatura@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH